Drug Innovation Ventures at Emory (DRIVE) and Antios Therapeutics announce license for hepatitis B drug

Antios raises $25 million in Series A financing Drug Innovation Ventures at Emory (DRIVE) today announced the licensing of ATI-2173, its leading candidate for the treatment of hepatitis B virus (HBV), to Antios Therapeutics (Antios), a biopharmaceutical company focused on the development of novel antiviral therapies for unmet medical needs. “We are very pleased that a DRIVE technology has a chance to positively affect so many patients in need,” says George Painter, PhD, chief executive officer of DRIVE.

Antios Therapeutics Raises $25 Million in Oversubscribed Series A Financing to Pursue Hepatitis B Cure

ATLANTA, Nov. 27, 2018 /PRNewswire/ – Antios Therapeutics, Inc. (“Antios”) today announced the completion of a US$25 million oversubscribed Series A financing led by Lumira Ventures and Domain Associates, two prominent life science venture capital firms. Other investors participating in the financing include CAM Capital, Delos Capital, Quantum Vista Capital, Fonds de solidarite FTQ and Georgia Research Alliance Venture Fund. The proceeds from this financing will be used to develop ATI-2173, Antios’ lead oral drug candidate for treating patients infected with Hepatitis B virus (HBV) and potentially Hepatitis D virus (HDV).